Your browser is no longer supported. Please, upgrade your browser.
ACAD ACADIA Pharmaceuticals Inc. weekly Stock Chart
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own0.30% Shs Outstand150.56M Perf Week-1.24%
Market Cap6.02B Forward P/E- EPS next Y-1.36 Insider Trans300.64% Shs Float150.54M Perf Month-5.17%
Income-267.90M PEG- EPS next Q-0.40 Inst Own93.00% Short Float7.37% Perf Quarter55.56%
Sales264.00M P/S22.80 EPS this Y-7.70% Inst Trans1.26% Short Ratio4.93 Perf Half Y69.55%
Book/sh2.69 P/B14.86 EPS next Y23.60% ROA-60.60% Target Price54.00 Perf Year74.43%
Cash/sh2.54 P/C15.76 EPS next 5Y26.50% ROE-71.00% 52W Range14.01 - 44.85 Perf YTD147.25%
Dividend- P/FCF- EPS past 5Y-34.30% ROI-51.90% 52W High-10.72% Beta2.75
Dividend %- Quick Ratio6.80 Sales past 5Y187.20% Gross Margin92.70% 52W Low185.80% ATR1.84
Employees477 Current Ratio6.80 Sales Q/Q45.70% Oper. Margin- RSI (14)58.30 Volatility2.41% 4.58%
OptionableYes Debt/Eq0.00 EPS Q/Q24.80% Profit Margin- Rel Volume0.41 Prev Close39.98
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume2.25M Price40.04
Recom1.90 SMA202.84% SMA5015.05% SMA20046.50% Volume701,267 Change0.15%
Oct-01-19Initiated RBC Capital Mkts Outperform $60
Sep-13-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19Upgrade Canaccord Genuity Hold → Buy $29 → $50
Jul-23-19Reiterated Needham Buy $40 → $34
Dec-10-18Initiated Canaccord Genuity Hold $23
Sep-21-18Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18Reiterated Stifel Hold $17 → $14
Aug-07-18Initiated Stifel Hold $17
Aug-06-18Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Oct-16-19 09:00AM  ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019 Business Wire
Oct-09-19 11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
Oct-08-19 06:00AM  Acadia Sees Strong Results in Dementia Treatment MoneyShow
Oct-07-19 09:00AM  ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress Business Wire
Oct-03-19 04:55PM  ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimers Disease (CTAD) 2019 Meeting Business Wire
Oct-02-19 06:37AM  We Think ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Easily Afford To Drive Business Growth Simply Wall St.
Sep-26-19 09:14AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Sep-25-19 04:05PM  ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 Business Wire
Sep-24-19 04:05PM  ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder Business Wire -7.07%
Sep-23-19 09:00AM  ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinsons Disease and Movement Disorders Business Wire
Sep-20-19 04:05PM  ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated
Sep-19-19 09:00AM  ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings Business Wire
Sep-17-19 11:00PM  ACADIA Pharmaceuticals Prices Public Offering of Common Stock Business Wire
04:02PM  ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
03:25PM  5 Top Stock Trades for Wednesday: BA, ACB, PINS InvestorPlace
Sep-11-19 10:23AM  3 Hot Biotechs with High Upside Potential TipRanks
Sep-10-19 01:20PM  'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis Benzinga +6.10%
11:41AM  ACADIA Surges on Early Success of Nuplazid Dementia Study Zacks
10:59AM  Will ACADIA Continue to Surge Higher? Zacks
08:39AM  Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? Motley Fool
07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga
Sep-09-19 05:38PM  Why Acadia Pharmaceuticals Stock Skyrocketed Today Motley Fool +63.24%
04:55PM  ACADIA Pharmaceuticals Help Lift Biotech ETFs ETF Trends
04:26PM  Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High Investor's Business Daily
04:13PM  What Happened in the Stock Market Today Motley Fool
02:33PM  Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis Benzinga
12:17PM  A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019 Benzinga
10:26AM  Options Hot as ACADIA Pharmaceuticals Stock Soars Schaeffer's Investment Research
09:05AM  ACADIA Enters Oversold Territory Zacks
07:31AM  [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment
07:26AM  Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint MarketWatch
06:30AM  ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis Business Wire
Sep-04-19 09:00AM  ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019 Business Wire
Aug-29-19 12:47PM  Top Ranked Momentum Stocks to Buy for August 29th Zacks
Aug-27-19 10:29AM  Is There An Opportunity With ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) 37% Undervaluation? Simply Wall St.
Aug-26-19 08:39AM  Top Ranked Momentum Stocks to Buy for August 26th Zacks
Aug-23-19 11:44AM  Top Ranked Momentum Stocks to Buy for August 23rd Zacks
Aug-20-19 08:34AM  Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment Zacks
Aug-16-19 10:42AM  Palatin's (PTN) to Report Q4 Earnings: What's in the Cards? Zacks
Aug-15-19 09:43AM  Top Ranked Momentum Stocks to Buy for August 15th Zacks
Aug-14-19 11:09AM  Top Ranked Momentum Stocks to Buy for August 14th Zacks
Aug-12-19 09:09AM  Top Ranked Momentum Stocks to Buy for August 12th Zacks
Aug-06-19 08:08AM  ACADIA Pharmaceuticals Inc. (ACAD) Shares March Higher, Can It Continue? Zacks
Aug-02-19 11:28AM  Edited Transcript of ACAD earnings conference call or presentation 31-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-01-19 12:06PM  Why Acadia Pharmaceuticals Stock Is Crushing It Today Motley Fool +16.64%
06:00AM  Acadia Pharmaceuticals Beats Expectations in Q2 Motley Fool
02:24AM  Acadia Pharmaceuticals (ACAD) Q2 2019 Earnings Call Transcript Motley Fool
Jul-31-19 06:55PM  Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results Business Wire
02:30PM  ACADIA Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:06AM  The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster Benzinga
Jul-24-19 10:32AM  Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-23-19 11:38AM  Why Acadia Pharmaceuticals Is Tanking Today Motley Fool -14.44%
11:00AM  Are These 2 Beaten-Down Biotech Stocks Worth Buying? Motley Fool
07:26AM  The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation Benzinga
Jul-22-19 04:53PM  Acadia stock drops as schizophrenia drug doesn't pass clinical trial MarketWatch
04:44PM  Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16% Reuters
04:14PM  Acadia's schizophrenia treatment fails to meet main goal of late-stage study Reuters
04:05PM  ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia Business Wire
01:56PM  Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study
Jul-17-19 09:00AM  ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019 Business Wire
Jul-11-19 06:36AM  Does ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Salary Reflect Performance? Simply Wall St.
Jun-25-19 08:50AM  New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners PR Newswire
Jun-11-19 08:23PM  Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy? Insider Monkey
06:59AM  When Will ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Turn A Profit? Simply Wall St.
Jun-04-19 09:00AM  ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference Business Wire
May-18-19 11:00AM  ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting Business Wire
May-09-19 03:57AM  Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 03:30PM  Why Acadia Pharmaceuticals Stock Slumped in April Motley Fool
May-07-19 09:00AM  ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019 Business Wire
May-02-19 03:24AM  Acadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript Motley Fool +7.78%
May-01-19 07:35PM  Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:29PM  Acadia: 1Q Earnings Snapshot Associated Press
04:05PM  ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
Apr-29-19 09:58PM  Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)? Insider Monkey
Apr-26-19 06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-25-19 09:00AM  ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder Business Wire
Apr-24-19 10:33AM  Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-19-19 09:11AM  Should ACADIA Pharmaceuticals (NASDAQ:ACAD) Be Disappointed With Their -30% Profit? Simply Wall St.
Apr-17-19 09:00AM  ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019 Business Wire -8.58%
Apr-11-19 09:00AM  ACADIA Pharmaceuticals Supports Parkinsons Disease Awareness Month and World Parkinsons Day with Local Educational Initiatives and Community Events Across the Country Business Wire
Apr-02-19 09:00AM  ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019 Business Wire
Apr-01-19 09:00AM  ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer Business Wire
Mar-29-19 07:20AM  Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-28-19 12:14PM  U.S. Stocks Are Still Stuck Because Uncertainty Is Everywhere
07:54AM  The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO Benzinga
Mar-27-19 04:10PM  Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology Business Wire
Mar-21-19 06:30AM  HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results CNW Group
Mar-13-19 01:18PM  Is ACADIA Pharmaceuticals Inc.s (NASDAQ:ACAD) Liquidity Good Enough? Simply Wall St.
Mar-05-19 10:40PM  Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
02:36PM  Why Acadia Pharmaceuticals Stock Perked Up in February Motley Fool
Mar-04-19 09:00AM  ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019 Business Wire
Feb-27-19 09:30AM  3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks +8.36%
01:05AM  Acadia Pharmaceuticals Inc (ACAD) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 04:05PM  ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
01:28PM  Big Pharma faces the Senate in drug price hearings Yahoo Finance Video
Feb-21-19 09:00AM  ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019 Business Wire
Feb-15-19 04:08PM  What's in the Cards for Bausch Health (BHC) Q4 Earnings? Zacks +6.02%
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Miller Eric AlejandroController & PAOOct 15Sale39.651475,829270Oct 17 06:26 PM
YANG MICHAEL J.EVP and CCOOct 15Sale39.6587734,7731,623Oct 17 06:25 PM
Stankovic Srdjan R.PresidentOct 15Sale39.651,03140,8791,937Oct 17 06:24 PM
DAVIS STEPHENCEOOct 15Sale39.652,983118,2762,954Oct 17 06:23 PM
DAVIS STEPHENCEOOct 10Option Exercise19.65120,2082,362,087120,208Oct 11 05:39 PM
DAVIS STEPHENCEOOct 10Sale40.19120,2084,831,0390Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Option Exercise19.6529,792585,41329,792Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Sale40.0029,7921,191,7100Oct 11 05:39 PM
BAKER BROS. ADVISORS LPDirectorSep 20Buy40.001,562,50062,500,00037,470,965Sep 20 04:28 PM
Miller Eric AlejandroController & PAOSep 11Sale41.184,645191,2810Sep 11 07:19 PM
Daly James MDirectorSep 09Option Exercise17.5230,000525,60030,000Sep 11 07:18 PM
Miller Eric AlejandroController & PAOSep 09Option Exercise28.7128,467817,21833,112Sep 11 07:19 PM
Daly James MDirectorSep 09Sale37.8030,0001,133,8600Sep 11 07:18 PM
Miller Eric AlejandroController & PAOSep 09Sale39.4928,4671,124,1624,645Sep 11 07:19 PM
Brege LauraDirectorJan 09Option Exercise2.1610,00021,60010,000Jan 11 04:32 PM
Brege LauraDirectorJan 09Sale20.0010,000200,0410Jan 11 04:32 PM
BAKER BROS. ADVISORS LPDirectorNov 30Buy17.0011,764,705199,999,98535,976,940Dec 04 05:00 PM